{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:02:50Z","timestamp":1776870170310,"version":"3.51.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Genetic variations in <jats:italic>TP53<\/jats:italic> gene are known to be important in chronic lymphocytic leukemia (CLL) and may cause its inactivation which is associated with an aggressive form of the disease. Single nucleotide polymorphism (rs1042522:G&amp;gt;C) in <jats:italic>TP53<\/jats:italic> gene at codon 72 encodes for arginine (Arg) or proline (Pro) variant which results in amino acid substitution affecting the apoptotic potential of <jats:italic>TP53<\/jats:italic> protein. The aim of this study was to assess the correlation between <jats:italic>TP53<\/jats:italic> codon 72 polymorphism and risk susceptibility as well as severity of CLL among Tunisian patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A case-control study was conducted in Tunisia from February 2019 to November 2021, 160 <jats:italic>de novo<\/jats:italic> CLL patients and 160 healthy volunteers matched in age and gender were involved. DNA was extracted from peripheral blood mononuclear cells and the rs1042522 was analyzed using PCR-RFLP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pro variant was associated with higher susceptibility to CLL than Arg variant (p= 0.023). A significant association was found between Pro variant and prognostic classification of Binet stage C (p= 0.001), low hemoglobin level (p= 0.003) and low platelet count (p= 0.016).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We suggest that Pro variant may increase the risk of developing CLL in our population and could be associated with the severity of the disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1272876","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:50:20Z","timestamp":1697431820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["TP53 Gene 72 Arg\/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Asma","family":"Ounalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imen","family":"Moumni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Mechaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Chakroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mbarka","family":"Barmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim El Elj","family":"Rhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Menif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Safra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"399\u2212404","DOI":"10.2147\/JBM.S221707","article-title":"Impact of TP53 gene promoter methylation on chronic lymphocytic leukemia pathogenesis and progression","volume":"10","author":"Saeed","year":"2019","journal-title":"J Blood Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1239\u221250","DOI":"10.1080\/14728222.2020.1832465","article-title":"Targeting p53 in chronic lymphocytic leukemia","volume":"24","author":"Moia","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026047","article-title":"The transactivation domains of the p53 protein","volume":"7","author":"Raj","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1\u221235","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.595187","article-title":"Mutant p53 in cancer progression and targeted therapies","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"705\u221211","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia. mars"},{"key":"B9","doi-asserted-by":"publisher","first-page":"423\u221236","DOI":"10.2147\/OTT.S265637","article-title":"Targeting TP53-mutated acute myeloid leukemia: research and clinical developments","volume":"15","author":"Granowicz","year":"2022","journal-title":"OTT"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.2147\/CMAR.S269624","article-title":"Characteristics and management of TP53-mutated diffuse large B-cell lymphoma patients","volume":"12","author":"Qin","year":"2020","journal-title":"Cancer Manage Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"209\u221227","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.610820","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge","volume":"10","author":"Molica","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1679\u2212705","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1956\u221268","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"218\u221227","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"160\u22129","DOI":"10.18502\/ijhoscr.v15i3.6846","article-title":"p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran","volume":"15","author":"Jalilian","year":"2021","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"364\u22129","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"378\u221282","DOI":"10.1093\/ajcp\/108.4.378","article-title":"Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)","volume":"108","author":"Moreau","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837531","article-title":"Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges","volume":"12","author":"Perutelli","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1266\u221287","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1840\u22127","DOI":"10.1182\/blood.V94.6.1840.418k06_1840_1847","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"37\u221250","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56\u221262","DOI":"10.1200\/GO.20.00276","article-title":"Chronic lymphocytic leukemia: prognostic factors at presentation in a resource-limited center","author":"Korubo","year":"2021","journal-title":"JCO Global Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"261\u22128","DOI":"10.1016\/j.htct.2020.05.005","article-title":"Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods","volume":"42","author":"Chauffaille M de","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6871\u22129","DOI":"10.7314\/APJCP.2014.15.16.6871","article-title":"TP53 polymorphisms in sporadic north Indian breast cancer patients. Asian pacific journal of cancer prevention","volume":"15","author":"Sharma","year":"2014","journal-title":"Asian Pacific J Cancer Prevention"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26\u221232","DOI":"10.29252\/rbmb.9.1.26","article-title":"Evaluation of TP53 codon 72, P21 codon 31, and MDM2 SNP309 polymorphisms in Iranian patients with acute lymphocytic leukemia","volume":"9","author":"Lotfi Garavand","year":"2020","journal-title":"Rep Biochem Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/jco.jco_12_22","article-title":"Chronic lymphocytic leukemia: Current approach to lab diagnosis","volume":"5","author":"Panda","year":"2022","journal-title":"J Curr Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2745\u221260","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"248\u221254","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: A comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"999\u22121007","DOI":"10.1002\/cam4.2788","article-title":"98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia","volume":"9","author":"Shi","year":"2020","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B32","doi-asserted-by":"publisher","first-page":"12073\u22129","DOI":"10.26355\/eurrev_202012_23996","article-title":"Association between TP53 polymorphisms and chronic lymphocytic leukemia","volume":"24","author":"Zhang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B33","first-page":"258\u221261","article-title":"TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia","volume":"36","author":"Bilous","year":"2014","journal-title":"Exp Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"459\u221265","DOI":"10.3233\/CBM-150485","article-title":"Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer","volume":"15","author":"Khan","year":"2015","journal-title":"Cancer Biomarkers."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3997\u22124005","DOI":"10.1007\/s13277-014-1657-y","article-title":"Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis","volume":"35","author":"Lu","year":"2014","journal-title":"Tumor Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"BSR20181832","DOI":"10.1042\/BSR20181832","article-title":"Association between TP53 rs1042522 gene polymorphism and the risk of Malignant bone tumors: a meta-analysis","volume":"39","author":"Huang","year":"2019","journal-title":"Bioscience Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118112","article-title":"Increased risk of cutaneous melanoma associated with p53 Arg72Pro polymorphism","volume":"10","author":"Geng","year":"2015","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2712808","article-title":"Association of TP53 rs1042522 C>G polymorphism with glioma risk in chinese children","volume":"2022","author":"Liao","year":"2022","journal-title":"BioMed Res Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"157\u221265","DOI":"10.26682\/sjuod.2020.23.2.17","article-title":"The relationship of gliomas with tp53 rs1042522 c > g and gliomas in duhok","volume":"23","author":"Nerweyi","year":"2020","journal-title":"J Duhok Univ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094874","article-title":"Evaluating the Association between p53 Codon 72 Arg>Pro Polymorphism and Risk of Ovary Cancer: A Meta-Analysis","volume":"9","author":"Alqumber","year":"2014","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1154\u22128","DOI":"10.1134\/S102279542209006X","article-title":"Association of polymorphic markers of the TP53, MDM2, and CDKN1A genes with the risk of ovarian cancer","volume":"58","author":"Brenner","year":"2022","journal-title":"Russ J Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1579\u221285","DOI":"10.31557\/APJCP.2019.20.5.1579","article-title":"TP53 gene 72 arg\/pro (rs1042522) single nucleotide polymorphism contribute to increase the risk of B-chronic lymphocytic leukemia in the Sudanese population","volume":"20","author":"Mohammed Basabaeen","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1113\u22128","DOI":"10.1016\/j.leukres.2005.12.014","article-title":"Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia","volume":"30","author":"Kochethu","year":"2006","journal-title":"Leuk Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s12032-014-0908-5","article-title":"TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia","volume":"31","author":"Dong","year":"2014","journal-title":"Med Oncol"},{"key":"B45","article-title":"Genotyping of p53 exon 4 codon 72 in Sudanese patients with lymphoid leukaemias","volume":"4","author":"Ahmed","year":"2013","journal-title":"International J Current Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"8291\u2212300","DOI":"10.1007\/s11033-022-07643-3","article-title":"Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children","volume":"49","author":"Skhoun","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"613\u221221","DOI":"10.31557\/APJCP.2023.24.2.613","article-title":"The Relationship between Gene Polymorphisms od the XRCC1 and TP53 with the Gender of Children with Acute Leukemia","volume":"24","author":"Usenova","year":"2023","journal-title":"Asian Pacific J Cancer Prev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3444\u22129","DOI":"10.7150\/jca.33063","article-title":"Association of the TP53 rs1042522 C>G polymorphism and hepatoblastoma risk in Chinese children","volume":"10","author":"Yang","year":"2019","journal-title":"J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"675\u221283","DOI":"10.1007\/s00109-020-02035-1","article-title":"Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes","volume":"99","author":"S\u0142omi\u0144ski","year":"2021","journal-title":"J Mol Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"36\u221244","DOI":"10.1016\/j.cancergencyto.2007.07.013","article-title":"p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia","volume":"179","author":"Lahiri","year":"2007","journal-title":"Cancer Genet Cytogenetics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"13\u22124","DOI":"10.1182\/blood-2020-141768","article-title":"Increase in mortality and second neoplasms in chronic lymphocytic leukemia with pro\/pro genotype of TP53 codon 72","volume":"136","author":"Cabero-Becerra","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2407-5-105","article-title":"In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis","volume":"5","author":"Sturm","year":"2005","journal-title":"BMC Cancer."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1272876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:50:25Z","timestamp":1697431825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1272876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":52,"alternative-id":["10.3389\/fonc.2023.1272876"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1272876","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"article-number":"1272876"}}